Dr. Robert Getzenberg, research director at Johns Hopkins Brady Urological Institute, said this morning that the EPCA-2 prostate cancer blood test is moving ahead and the law suit filed against him and the University of Pittsburgh is “for money.”

We spoke with Dr. Getzenberg by phone at 9.50 this morning after leaving a message yesterday with his staff. He returned the call from his Johns Hopkins office, sounding up-beat.

“The science remains the same,” Getzenberg said about the progress of the EPCA-2 prostate cancer diagnostic test. “Everything is solid.”